Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Total Current Liabilities (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Total Current Liabilities for 7 consecutive years, with $195.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 99.4% year-over-year to $195.4 million, compared with a TTM value of $195.4 million through Dec 2025, up 99.4%, and an annual FY2025 reading of $195.4 million, up 99.4% over the prior year.
  • Total Current Liabilities was $195.4 million for Q4 2025 at Avidity Biosciences, up from $169.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $195.4 million in Q4 2025 and bottomed at $16.3 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $70.1 million, with a median of $50.3 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities surged 106.19% in 2022, then increased 13.22% in 2025.
  • Year by year, Total Current Liabilities stood at $29.7 million in 2021, then skyrocketed by 75.02% to $51.9 million in 2022, then skyrocketed by 55.43% to $80.7 million in 2023, then grew by 21.49% to $98.0 million in 2024, then surged by 99.4% to $195.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for RNA at $195.4 million in Q4 2025, $169.9 million in Q3 2025, and $135.1 million in Q2 2025.